The DOI matches its Crossref record.
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects
Abstract
In this longitudinal study of 77 patients with mild cognitive impairment (MCI), the authors analyzed whether levels of tau protein phosphorylated at threonine 231 (p-tau(231)) in CSF correlate with progression of cognitive decline. High CSF p-tau(231) levels at baseline, but not total tau protein levels, correlated with cognitive decline and conversion from MCI to AD. Independently, old age and APOE-epsilon 4 carrier status were predictive as well. Our data indicate that an increased p-tau(231) level is a potential risk factor for cognitive decline in patients with MCI.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“pThr231Tau is an early marker of AD pathology that correlates well with cognitive decline (Buerger et al., 2002, Luna-Muñoz et al., 2007).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Buerger et al., 2002
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 10
- 10.1001/jama.1995.03520400044042 · DOI
- 10.1016/S0304-3940(00)01178-2 · DOI
- 10.1002/ana.111 · DOI
- 10.1016/S0197-4580(98)00071-2 · DOI
- 10.1385/MN:24:1-3:087 · DOI
- Consensus Report of the Working Group on “Molecular and Biochemical Markers of Alzheimer’s Disease.” The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109–116. · DOI
- 10.1111/j.1600-0447.1987.tb02906.x · DOI
- 10.1016/S0197-4580(99)00107-4 · DOI · Paper page
- 10.1016/S0304-3940(99)00617-5 · DOI
- 10.1006/exnr.2000.7501 · DOI
Cited by
Sorted by citations
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationPlasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationBuerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Self-citationHampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434
Self-citation
Metadata
- Authors
- Buerger, K., Teipel, S. J., Zinkowski, R., Blennow, K., Arai, H., Engel, R., Hofmann–Kiefer, K., McCulloch, C., Ptok, U., Heun, R., Andreasen, N., DeBernardis, J., Kerkman, D., Moeller, H. J., Davies, P., & Hampel, H.
- Affiliations
- From the Dementia Research Section and Memory Clinic (Drs. Buerger, Teipel, Moeller, Engel, and Hampel), Alzheimer Memorial Center, Department of Psychiatry, and the Department of Anesthesiology (Dr. Hofmann–Kiefer), Ludwig-Maximilian University, Munich, Germany; Molecular Geriatrics Corporation (Drs. Zinkowski, DeBernardis, and Kerkman, and C. McCulloch), Vernon Hills, IL; the Department of Clinical Neuroscience (Dr. Blennow), Unit of Neurochemistry, University of Göteborg, Sahlgren’s University...
- Venue
- Neurology
- Published
- 2002-08-27
- Volume
- 59
- Issue
- 4
- Pages
- 627-629
- ISSN
- 0028-3878
- 1526-632X
- Cited by
- 187
- References
- 0
- Language
- en
- Update notices
- correction (2004-09-28)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. https://app.cochat.ai/papers/10.1212/wnl.59.4.627
- The paper
- Buerger, K., Teipel, S. J., Zinkowski, R., Blennow, K., Arai, H., Engel, R., Hofmann–Kiefer, K., McCulloch, C., Ptok, U., Heun, R., Andreasen, N., DeBernardis, J., Kerkman, D., Moeller, H. J., Davies, P., & Hampel, H. (2002). CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. https://doi.org/10.1212/wnl.59.4.627
